Male doctor talking to elderly female patient

Chronic Inflammatory Demyelinating Polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neuromuscular disease and the trigger is unknown.1,2

The pathophysiology of CIDP is thought to be based on the autoimmune destruction of peripheral nerve myelin,2 leading to characteristic clinical symptoms of progressive limb weakness with impaired sensory function.2,3 Diagnosis of CIDP is challenging, and laboratory features, electrodiagnostic and clinical criteria are key.4

Neurological condition educational diagram

Epidemiology

The age of CIDP onset is usually 40 to 60 years, although it can occur at any age. CIDP is twice as common in men than women.5 Available evidence suggests that ethnicity does not influence rates of CIDP.6

Scientific Congresses and Resources

This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas. Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling are left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.

American College of Allergy, Asthma & Immunology (ACAAI), 2026

November 12 - 16, 2026

Global meeting featuring thought leaders from around the world focused on advancing patient care in allergy and immunology.

Immunoglobulin National Society (IgNS), 2026

October 15 - 18, 2026

National conference of IgNS bringing together professionals and practitioners from all disciplines and clinical specialties to advance Ig therapy practice, while providing networking and comprehensive education opportunities.

  • Patient Perspectives On Immunoglobulin Therapy And Interest In A Dual-Vial Immunoglobulin Delivery Device For CIDP And PIDD
  • Healthcare Utilization In Primary Immunodeficiency Diseases: Real-World Comparisons Of Immunoglobulin Replacement Therapy Use And Administration Modalities

HyQvia® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]

  • Real-World Treatment Patterns And Functional Outcomes In Adults With CIDP Receiving IVIG 10% Solution In The USA

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2026

September 29 - October 2, 2026

Annual meeting dedicated to the advancement of neuromuscular, musculoskeletal, and electrodiagnostic medicine.

HyQvia® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]

  • Outcomes With Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10 Percent (Hyqvia) In Chronic Inflammatory Demyelinating Polyradiculoneuropathy And Diabetes: Post Hoc Analysis Of ADVANCE-CIDP 1
  • Real-World Functional Outcomes And Treatment Stability With Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10 Percent (Hyqvia) In Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Aspen Allergy Conference (AAC), 2026

July 22 - 26, 2026

Annual conference that invites state-of-the-art speakers from around the world to discuss basic science and clinical topics on allergy, asthma, and immunology.

Takhzyro® (lanadelumab-flyo)

  • Physician-Reported Attack Rates and Attack Characteristics Among Patients With Hereditary Angioedema Who Extended Dosing With Lanadelumab: An EMPOWER Study Analysis

Peripheral Nerve Society (PNS), 2026

June 13 - 16, 2026

The largest peripheral nerve meeting globally, offering the latest international research across specialties in peripheral neuropathy.

  • Post-Relapse IVIG Response In CIDP: Systematic Literature Review, Meta-Analysis and Descriptive Comparison With Efgartigimod PH20
  • Plasma Proteomics: A Tool To Discover Biomarkers For Disease Monitoring and Treatment Responses in CIDP

HyQvia® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]

  • Local Treatment-Emergent Adverse Events In Patients With CIDP Treated With fSCIG During The ADVANCE-CIDP 1/-CIDP 3 Trials

Eastern Allergy Conference (EAC), 2026

May 28 - 31, 2026

Regional annual conference discussing the most current information from top experts in allergy, asthma, and immunology.

Takhzyro® (lanadelumab-flyo)

  • Cost per Number-Needed-to-Treat Estimates for Patients With Hereditary Angioedema Treated With Long-Term Prophylaxis
  • Longitudinal Survey of Adult Patients With Hereditary Angioedema Receiving Long-Term Prophylaxis With Lanadelumab: 12-Month Findings
  • Physician-Reported Attack Rates and Attack Characteristics Among Patients With Hereditary Angioedema Who Extended Dosing With Lanadelumab: An EMPOWER Study Analysis

Clinical Immunology Society (CIS), 2026

May 6 - 9, 2026

Annual meeting with the goal of providing a stimulating forum with presentations and discussions on the latest advances in clinical immunology, including primary

immunodeficiencies and immune dysregulatory diseases.

  • Characteristics, Efficacy and Safety Profile of a Ready-To-Use Low-IgA Immunoglobulin 10% Replacement Therapy

HyQvia® [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]

  • Clinical Implications of Baseline-Corrected Total Immunoglobulin G Levels: Pharmacokinetic Data From a Phase 3, Open-Label Study of Patients with Primary Immunodeficiency Disease Treated with fSCIG 10%

National Home Infusion Association (NHIA), 2026

April 18 - 22, 2026

Brings together home and alternate site infusion professionals for four days of networking, education, and exhibits. The expo features companies displaying the latest products and services supporting the industry.

American Academy of Neurology (AAN), 2026

April 18 - 22, 2026

Each year, the American Academy of Neurology's Annual Meeting offers a robust lineup of diverse learning opportunities covering nearly every topic and subspecialty, helping you stay up to date on the latest trusted science and essential education.

  • Analysis of Local Treatment-emergent Adverse Events in Patients with CIDP Treated with fSCIG During the ADVANCE-CIDP 1 and Long-term ADVANCE-CIDP 3 Trials

Consortium of Independent Immunology Clinics (CIIC), 2026

April 17 - 19, 2026

Semi-annual CIIC conferences provide a unique opportunity to network with experts and prospective partners in the allergy, asthma and immunology space.

Takhzyro® (lanadelumab-flyo)

  • Physician-Reported Attack Rates and Attack Characteristics Among Patients With Hereditary Angioedema Who Extended Dosing With Lanadelumab: An EMPOWER Study Analysis

Annual Meeting American Academy of Allergy, Asthma and Immunology (AAAAI), 2026

February 27 - March 2, 2026

Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.

  • Social Determinants of Health Associated With Healthcare Resource Utilization for Hereditary Angioedema

Takhzyro® (lanadelumab-flyo)

  • Longitudinal Survey of Adult Patients with Hereditary Angioedema Receiving Long-Term Prophylaxis with Lanadelumab: 12 Month Findings

Medications

This resource provides information on Takeda medications available in the Chronic Inflammatory Demyelinating Polyneuropathy category and is not intended to represent a complete list of therapeutic options.

Gammagard Liquid®

[Immune Globulin Infusion (Human)] 10%

HyQvia®

[Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]

Videos

Watch videos focused on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

CIDP Patient Video: Chris

In this video, Chris describes his experience of being diagnosed and living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

CIDP Patient Video: Julie

Julie shares her experience of being diagnosed with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and the challenges of living with this disorder.

 

Additional Resources

Find materials to help foster a deeper understanding of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

pdf-icon569876

Diagnosis of CIDP Fact Sheet

An overview of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) clinical presentation and diagnostic considerations.

pdf-icon569877

Guideline Recommendations on the Diagnosis of CIDP Fact Sheet

An overview of the task force guideline recommendations for diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Unable to find what you're looking for?

         

Medical inquiry submission

Submit a Medical Inquiry

Click the button below to send us your Medical Inquiry. We are committed to responding to your inquiries, and will get back to you as soon as possible.

Phone contact information

Contact Us

Contact us using the number below to:

  • Report an adverse event or product quality complaint
  • Speak to a member of the team about your clinical and scientific questions.

Call 1-877-TAKEDA-7 (1-877-825-3327)

Chat with us

Chat with Us

Speak with a Medical Information Specialist Monday-Friday 8am-6pm ET.